Evidence map›Paper›PMID 28865422›Full record

ArticleBMC cancer2017

Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa.

Aggrey Semeere, Esther Freeman, Megan Wenger, David Glidden, Mwebesa Bwana, Micheal Kanyesigye, Fredrick Chite Asirwa, Elyne Rotich, Naftali Busakhala, Emmanuel Oga and 12 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 14 institutions in 8 countries.

Aggrey SemeereInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. asemeere@gmail.com.
Esther FreemanMassachusetts General Hospital, Boston, MA, USA.
Megan WengerUniversity of California San Francisco, San Francisco, CA, United States.
David GliddenUniversity of California San Francisco, San Francisco, CA, United States.
Mwebesa BwanaMbarara University of Science and Technology, Mbarara, Uganda.
Micheal KanyesigyeMbarara University of Science and Technology, Mbarara, Uganda.
Fredrick Chite AsirwaIndiana University, Indianapolis, IN, USA.
Elyne RotichAMPATH, Moi University, Eldoret, Kenya.
Naftali BusakhalaAMPATH, Moi University, Eldoret, Kenya.
Emmanuel OgaInstitute of Human Virology, Abuja, Nigeria.
Elima Jedy-AgbaInstitute of Human Virology, Abuja, Nigeria.
Vivian KwagheUniversity of Abuja Teaching Hospital, Gwagwalada, Nigeria.
Kenneth IregbuNational Hospital of Abuja, Abuja, Nigeria.
Clement AdebamowoInstitute of Human Virology, Abuja, Nigeria.
Antoine JaquetINSERM U1219 & ISPED, Université Bordeaux, Bordeaux, France.
Francois DabisINSERM U1219 & ISPED, Université Bordeaux, Bordeaux, France.
Sam PhiriLighthouse Trust Clinic, Lilongwe, Malawi.
Julia BohliusUniversity of Bern, Bern, Switzerland.
Matthias EggerUniversity of Bern, Bern, Switzerland.
Constantin T YiannoutsosIndiana University, Indianapolis, IN, USA.
Kara Wools-KaloustianIndiana University, Indianapolis, IN, USA.
Jeffrey MartinUniversity of California San Francisco, San Francisco, CA, United States.
Moi University · KEUniversity of California, San Francisco · USIndiana University – Purdue University Indianapolis · USInstitute of Human Virology · NGMbarara University of Science and Technology · UGUniversity of Bern · CHBordeaux Population Health · FRInserm · FRLighthouse Trust · MWLondon School of Hygiene & Tropical Medicine · GBMakerere University · UGMassachusetts General Hospital · USNational Hospital Abuja · NGUniversity of Abuja Teaching Hospital · NG

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7M
Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8M
WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
DERMATOLOGY TRAINING GRANTT32AR007098 · NIAMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI THOMAS S. KUPPER · 1986 to 2026
$8.1M
Why do Patients Develop KSU54CA190153 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAMBUGU, ANDREW DDUNGU, MARTIN, JEFFREY N · 2014 to 2019
$3.6M
Uganda-UCSF Research Training in HIV-Associated MalignanciesD43CA153717 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARTIN, JEFFREY N · 2010 to 2013
$1.9M
NCI NIH HHS D43 CA153717NCI NIH HHS U54 CA190153NIAID NIH HHS P30 AI027763NIAID NIH HHS U01 AI069911NIAID NIH HHS U01 AI069919NIAID NIH HHS U01 AI069924NIAID NIH HHS U01 AI096299NIAMS NIH HHS T32 AR007098
6 · The paper itself

Abstract

backgroundThroughout most of sub-Saharan Africa (and, indeed, most resource-limited areas), lack of death registries prohibits linkage of cancer diagnoses and precludes the most expeditious approach to determining cancer survival. Instead, estimation of cancer survival often uses clinical records, which have some mortality data but are replete with patients who are lost to follow-up (LTFU), some of which may be caused by undocumented death. The end result is that accurate estimation of cancer survival is rarely performed. A prominent example of a common cancer in Africa for which survival data are needed but for which frequent LTFU has precluded accurate estimation is Kaposi sarcoma (KS).

methodsUsing electronic records, we identified all newly diagnosed KS among HIV-infected adults at 33 primary care clinics in Kenya, Uganda, Nigeria, and Malawi from 2009 to 2012. We determined those patients who were apparently LTFU, defined as absent from clinic for ≥90 days at database closure and unknown to be dead or transferred. Using standardized protocols which included manual chart review, telephone calls, and physical tracking in the community, we attempted to update vital status amongst patients who were LTFU.

resultsWe identified 1222 patients with KS, of whom 440 were LTFU according to electronic records. Manual chart review revealed that 18 (4.1%) were classified as LFTU due to clerical error, leaving 422 as truly LTFU. Of these 422, we updated vital status in 78%; manual chart review was responsible for updating in 5.7%, telephone calls in 26%, and physical tracking in 46%. Among 378 patients who consented at clinic enrollment to be tracked if they became LTFU and who had sufficient geographic contact/locator information, we updated vital status in 88%. Duration of LTFU was not associated with success of tracking, but tracking success was better in Kenya than the other sites.

conclusionIt is feasible to update vital status in a large fraction of patients with HIV-associated KS in sub-Saharan Africa who have become LTFU from clinical care. This finding likely applies to other cancers as well. Updating vital status amongst lost patients paves the way towards accurate determination of cancer survival.

Indexed as

EpidemicsAdultAfrica South of the SaharaAIDS-Related Opportunistic InfectionsAnti-HIV AgentsFemaleHIV InfectionsHumansLost to Follow-UpMaleSarcoma, KaposiAnti-HIV AgentsCancerHIV/AIDSKaposi sarcomaLoss to follow-upMortalityResource-limited settingsSub-Saharan AfricaSurvivalTracingTrackingUpdating vital status

Identifiers

PMID28865422
PMCPMC5581434
OpenAlexW2753292059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.